GR3035195T3 - Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them. - Google Patents
Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them.Info
- Publication number
- GR3035195T3 GR3035195T3 GR20010400013T GR20010400013T GR3035195T3 GR 3035195 T3 GR3035195 T3 GR 3035195T3 GR 20010400013 T GR20010400013 T GR 20010400013T GR 20010400013 T GR20010400013 T GR 20010400013T GR 3035195 T3 GR3035195 T3 GR 3035195T3
- Authority
- GR
- Greece
- Prior art keywords
- chlorophyll
- chl
- conjugates
- bchl
- preparation
- Prior art date
Links
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 title abstract 3
- DSJXIQQMORJERS-AGGZHOMASA-M bacteriochlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@H](CC)[C@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 DSJXIQQMORJERS-AGGZHOMASA-M 0.000 title abstract 2
- 229930002875 chlorophyll Natural products 0.000 title abstract 2
- 235000019804 chlorophyll Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000002428 photodynamic therapy Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108010003118 Bacteriochlorophylls Proteins 0.000 abstract 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 abstract 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 239000003504 photosensitizing agent Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
- C07K14/685—Alpha-melanotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL102645A IL102645A (en) | 1992-07-26 | 1992-07-26 | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3035195T3 true GR3035195T3 (en) | 2001-04-30 |
Family
ID=11063865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010400013T GR3035195T3 (en) | 1992-07-26 | 2001-01-10 | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US5726169A (el) |
| EP (1) | EP0584552B1 (el) |
| JP (1) | JP3612343B2 (el) |
| CN (1) | CN1040212C (el) |
| AT (1) | ATE196850T1 (el) |
| AU (1) | AU674315B2 (el) |
| CA (1) | CA2101227C (el) |
| DE (1) | DE69329538T2 (el) |
| DK (1) | DK0584552T3 (el) |
| ES (1) | ES2153367T3 (el) |
| GR (1) | GR3035195T3 (el) |
| HU (1) | HU221186B1 (el) |
| IL (1) | IL102645A (el) |
| PL (2) | PL173150B1 (el) |
| PT (1) | PT584552E (el) |
| ZA (1) | ZA935310B (el) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147195A (en) * | 1993-07-26 | 2000-11-14 | Yeda Research And Development Co., Ltd. | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them |
| IL116126A0 (en) | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
| GB9625895D0 (en) | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
| CN1074771C (zh) * | 1996-12-30 | 2001-11-14 | 中国科学院长春应用化学研究所 | 聚合物载体茂金属催化剂的制备 |
| AU6028598A (en) * | 1997-01-09 | 1998-08-03 | Emory University | Non-iron metalloporphyrins and methods of use |
| DE19731741A1 (de) * | 1997-07-23 | 1999-01-28 | Deutsches Krebsforsch | Konjugat zur Unterscheidung von krankhaftem und gesundem Gewebe |
| US6284223B1 (en) * | 1998-10-15 | 2001-09-04 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
| US6652836B2 (en) | 1998-10-15 | 2003-11-25 | Fluoroprobe, Inc. | Method for viewing tumor tissue located within a body cavity |
| US6299860B1 (en) | 1998-10-15 | 2001-10-09 | Fluoro Probe, Inc. | Method for viewing diseased tissue located within a body cavity |
| HU228208B1 (en) | 1998-12-09 | 2013-01-28 | Yeda Res & Dev | Palladium-substituted bacteriochlorophyll derivatives and use thereof |
| IL133253A0 (en) | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
| US7045117B2 (en) * | 1999-12-01 | 2006-05-16 | Yeda Research And Development Co. Ltd. | Method for tumor diagnosis comprising administering of palladium-substituted bacteriochlorophyll derivatives |
| EP1267935A2 (en) * | 2000-01-12 | 2003-01-02 | Light Sciences Corporation | Novel treatment for eye disease |
| US7235685B2 (en) | 2001-07-03 | 2007-06-26 | Mallinckrodt, Inc. | Aromatic sulfenates for type I phototherapy |
| US20020169107A1 (en) * | 2001-01-19 | 2002-11-14 | Mallinckrodt Inc. | Novel aromatic azides for type I phototherapy |
| WO2002008174A1 (en) * | 2000-07-26 | 2002-01-31 | Patrick Anthony Riley | Phenylethylamine derivatives and their use in the treatment of melanoma |
| WO2002013820A1 (en) * | 2000-08-11 | 2002-02-21 | Ceramoptec Industries, Inc. | Photosensitizing ointment |
| AU2006200164B2 (en) * | 2001-04-09 | 2007-03-08 | Oncofluor, Inc. | Method for viewing tumor tissue located within a body cavity |
| IL148921A0 (en) * | 2002-03-26 | 2002-09-12 | Peptor Ltd | Photo active backbone cyclized somatostatin analogs for optical imaging and photodynamic therapy |
| BR0304716A (pt) | 2002-05-08 | 2004-07-13 | Yeda Res & Dev | Método para formação de imagens de mri-bold on line, sensibilizada |
| IL152900A0 (en) * | 2002-11-17 | 2003-06-24 | Yeda Res & Dev | Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses |
| GB0323358D0 (en) * | 2003-10-06 | 2003-11-05 | Green Grass Design Ltd | Novel compounds and processes |
| PT1753457T (pt) | 2004-06-07 | 2016-11-10 | Yeda Res & Dev | Derivados catiónicos de bacterioclorofilas e utilizações dos mesmos |
| US7947827B2 (en) * | 2006-06-30 | 2011-05-24 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Pharmaceutical formulation comprising a metaloporphyrin and method for its purification and use |
| US9957293B2 (en) | 2006-08-23 | 2018-05-01 | Yeda Research And Development Company Ltd. | Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
| CA2661319C (en) * | 2006-08-23 | 2015-12-01 | Yeda Research And Development Co. Ltd | Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses |
| CA2699912A1 (en) | 2007-09-19 | 2009-03-26 | Oncofluor, Inc. | Method for imaging and treating organs and tissues |
| FR2924021B1 (fr) * | 2007-11-27 | 2010-08-13 | Du Vernet Michele Eymard | Composition pour le traitement de la peau par therapie photodynamique |
| EP2244787A1 (en) * | 2008-01-28 | 2010-11-03 | Yeda Research And Development Company Ltd. | Endoscopic imaging photodynamic therapy system and methods of use |
| AU2009216681A1 (en) * | 2008-02-22 | 2009-08-27 | Clinuvel Pharmaceuticals Limited | Method for treatment of photosensitivity and phototoxicity |
| WO2009107139A1 (en) * | 2008-02-27 | 2009-09-03 | Yeda Research And Development Co. Ltd | Rgd-(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors |
| CA2846011C (en) | 2011-08-23 | 2019-10-15 | Yeda Research And Development Co.Ltd. | (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders |
| EP2934303B1 (en) | 2012-12-19 | 2019-09-04 | The Research Foundation for the State University of New York | Compositions and method for light triggered release of materials from nanovesicles |
| CN105579063A (zh) * | 2013-06-05 | 2016-05-11 | 法尔哈德·哈菲泽 | 包括光活化活性组分的施用组合物的方法和具有给予药物组合物的方案的药物组合物 |
| RU2536109C1 (ru) * | 2013-07-25 | 2014-12-20 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ комбинированной обработки склерального ложа после эндорезекции внутриглазного новообразования |
| RU2536116C1 (ru) * | 2013-07-25 | 2014-12-20 | федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ фотодинамической обработки склерального ложа после эндорезекции внутриглазного новообразования |
| SG10201506686WA (en) * | 2015-08-24 | 2017-03-30 | Agency Science Tech & Res | Conjugates |
| CN111171030B (zh) * | 2018-11-12 | 2022-11-22 | 浙江海正药业股份有限公司 | 细菌叶绿素衍生物及其制备方法 |
| CN115093422B (zh) * | 2022-06-15 | 2023-06-20 | 西北工业大学 | 一种基于代谢标记策略的新型光敏剂及其制备方法和应用 |
| CN116585530B (zh) * | 2023-05-05 | 2024-02-02 | 暨南大学 | 一种高效产氧的叶绿体复合水凝胶及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5156840A (en) * | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US4977177A (en) * | 1985-04-30 | 1990-12-11 | Nippon Petrochemicals Company, Ltd. | Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents |
| HU204856B (en) * | 1987-08-12 | 1992-02-28 | Orszagos Mueszaki Fejlesztesi | Process for releasing cell mixtures and tissues from undesired populations and for producing monoclonal antibody - hematoporphyrin conjugates |
| US4876190A (en) * | 1987-10-21 | 1989-10-24 | Becton Dickinson & Company | Peridinin-chlorophyll complex as fluorescent label |
| EP0350948B1 (en) * | 1988-07-14 | 1998-03-18 | Toyohakka Kogyo Kabushiki Kaisha | Porphyrin derivatives |
| US5002962A (en) * | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5567687A (en) * | 1989-03-06 | 1996-10-22 | University Of Texas | Texaphyrins and uses thereof |
| US5171741A (en) * | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5238940A (en) * | 1990-03-22 | 1993-08-24 | Quadra Logic Technologies Inc. | Compositions for photodynamic therapy |
| DE4121876A1 (de) * | 1991-07-02 | 1993-01-14 | Scheer Hugo | Modifizierte bakteriochlorophylle, verfahren zu ihrer herstellung und ihre verwendung |
| US5330741A (en) * | 1992-02-24 | 1994-07-19 | The Regents Of The University Of California | Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors |
-
1992
- 1992-07-26 IL IL102645A patent/IL102645A/en not_active IP Right Cessation
-
1993
- 1993-07-22 AU AU42148/93A patent/AU674315B2/en not_active Ceased
- 1993-07-22 ZA ZA935310A patent/ZA935310B/xx unknown
- 1993-07-23 CA CA002101227A patent/CA2101227C/en not_active Expired - Fee Related
- 1993-07-23 HU HU9302149A patent/HU221186B1/hu not_active IP Right Cessation
- 1993-07-26 EP EP93111942A patent/EP0584552B1/en not_active Expired - Lifetime
- 1993-07-26 AT AT93111942T patent/ATE196850T1/de not_active IP Right Cessation
- 1993-07-26 PT PT93111942T patent/PT584552E/pt unknown
- 1993-07-26 JP JP22632893A patent/JP3612343B2/ja not_active Expired - Fee Related
- 1993-07-26 US US08/097,384 patent/US5726169A/en not_active Expired - Fee Related
- 1993-07-26 CN CN93116862A patent/CN1040212C/zh not_active Expired - Fee Related
- 1993-07-26 PL PL93299803A patent/PL173150B1/pl not_active IP Right Cessation
- 1993-07-26 ES ES93111942T patent/ES2153367T3/es not_active Expired - Lifetime
- 1993-07-26 DE DE69329538T patent/DE69329538T2/de not_active Expired - Fee Related
- 1993-07-26 PL PL93319910A patent/PL173128B1/pl not_active IP Right Cessation
- 1993-07-26 DK DK93111942T patent/DK0584552T3/da active
-
1995
- 1995-06-05 US US08/461,243 patent/US5955585A/en not_active Expired - Fee Related
- 1995-07-31 US US08/463,950 patent/US5650292A/en not_active Expired - Fee Related
-
2001
- 2001-01-10 GR GR20010400013T patent/GR3035195T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5955585A (en) | 1999-09-21 |
| HU221186B1 (en) | 2002-08-28 |
| PL299803A1 (en) | 1994-02-07 |
| JP3612343B2 (ja) | 2005-01-19 |
| DE69329538D1 (de) | 2000-11-16 |
| EP0584552A2 (en) | 1994-03-02 |
| IL102645A (en) | 1998-02-22 |
| ATE196850T1 (de) | 2000-10-15 |
| JPH0733772A (ja) | 1995-02-03 |
| AU4214893A (en) | 1994-01-27 |
| CA2101227C (en) | 2002-11-12 |
| HUT64949A (en) | 1994-03-28 |
| AU674315B2 (en) | 1996-12-19 |
| CN1088210A (zh) | 1994-06-22 |
| PT584552E (pt) | 2001-04-30 |
| CN1040212C (zh) | 1998-10-14 |
| ES2153367T3 (es) | 2001-03-01 |
| HU9302149D0 (en) | 1993-10-28 |
| PL173128B1 (pl) | 1998-01-30 |
| DK0584552T3 (da) | 2001-02-05 |
| US5650292A (en) | 1997-07-22 |
| US5726169A (en) | 1998-03-10 |
| EP0584552A3 (en) | 1994-08-17 |
| EP0584552B1 (en) | 2000-10-11 |
| IL102645A0 (en) | 1993-01-14 |
| CA2101227A1 (en) | 1994-01-27 |
| DE69329538T2 (de) | 2001-06-07 |
| ZA935310B (en) | 1994-02-11 |
| PL173150B1 (pl) | 1998-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0584552A3 (en) | Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them | |
| EP0259904B1 (en) | Advanced anticancer therapy and cytotoxic medicaments for its implementation | |
| ES2230860T3 (es) | Sistema de administracion de farmacos que comprende un peptido homeobos y un agente citotoxico o antineoplasico. | |
| ES2736505T3 (es) | Nuevo conjugado estable de anticuerpo-fármaco, método de preparación y uso del mismo | |
| DE3166150D1 (en) | N-(vinblastinoyl-23) derivatives of amino acids and peptides and their preparation | |
| DK0662827T3 (da) | Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer | |
| HUT56583A (en) | Process for producing peptide derivatives and pharmaceutical and diagnostic compositions comprising such compounds | |
| NO180417B (no) | Syrelabile linkermolekyler | |
| DK601786A (da) | Hidtil ukendte prokoagulationsproteiner | |
| NZ516381A (en) | Lung tumor proteins in the therapy and diagnosis of lung cancer | |
| WO2006092230A2 (de) | Proteinbindende camptothecin-peptid-derivate und diese enthaltende arzneimittel | |
| IL72630A (en) | Growth hormone-releasing peptides,their preparation and pharmaceutical preparations therefrom | |
| NZ504938A (en) | Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen | |
| WO2007113386A1 (en) | Peptide conjugates | |
| EP2046813B1 (de) | Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel | |
| EP0638067A4 (en) | NEW PROPOXYPHENE DERIVATIVES AND THEIR PROTEIN AND POLYPEPTIDE LABELS AND CONJUGATES. | |
| Hudecz et al. | Immunoconjugate design: a predictive approach for coupling of daunomycin to monoclonal antibodies | |
| AU635721B2 (en) | Targetting agents | |
| WO1991000111A1 (en) | Targetting agents | |
| CN115814111A (zh) | 一种近红外荧光adc免疫制剂及其制备方法与应用 | |
| Martin et al. | Photoaffinity labelling of the vasoactive-intestinal-peptide-binding site on intact human colonic adenocarcinoma cell line HT29-D4. Synthesis and use of photosensitive vasoactive-intestinal-peptide derivatives | |
| EP0368131A3 (en) | Neoglucoproteins, their preparation and use | |
| AU2002362210A1 (en) | Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon | |
| GR1002475B (el) | Μεθοδος παρασκευης πεπτιδικων παραγωγων. | |
| TH44562A (th) | สารคู่ที่ใช้ในการรักษามะเร็งต่อมลูกหมาก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |